Arbidol Hydrochloride (Arbidol HCl), also known as Umifenovir, with CAS number 131707-23-8, stands as a prominent broad-spectrum antiviral compound. This fine white to off-white crystalline powder is a pharmaceutical intermediate recognized for its high purity, typically exceeding 99%. Its well-defined chemical formula, C22H26BrClN2O3S, underpins its unique mechanism of action against a variety of viral pathogens.

Historically, Arbidol HCl has been extensively utilized in the treatment and prophylaxis of influenza, including both influenza A and B viruses. Its efficacy stems from its ability to inhibit viral fusion, a crucial step in the viral lifecycle where the virus's lipid shell merges with the host cell membrane. By blocking this process, Arbidol HCl effectively prevents viral entry and subsequent replication within host cells. Beyond this direct antiviral effect, scientific studies indicate that Umifenovir also possesses immunomodulatory properties, notably by inducing interferon production, which significantly enhances the body's natural immune response. This dual action contributes to its effectiveness in reducing the severity and duration of influenza symptoms, and plays a vital role in preventing the development of post-influenza complications during epidemic periods.

Recent global health challenges have brought Umifenovir into the spotlight for its potential applications beyond traditional influenza treatment. Extensive research, including both in vitro studies and randomized controlled clinical trials, has explored its antiviral activity against a broader spectrum of coronaviruses, notably SARS-CoV-2, the causative agent of COVID-19. In laboratory settings, Umifenovir has demonstrated significant inhibitory effects against various human coronaviruses, including seasonal strains like HCoV-229E and HCoV-OC43, as well as the more pathogenic SARS-CoV and SARS-CoV-2. These studies highlight its capacity to suppress viral replication and reduce viral titers, suggesting a promising role in combating emerging viral threats.

Furthermore, clinical investigations have provided compelling evidence regarding its therapeutic benefits in patients infected with SARS-CoV-2. One notable randomized controlled trial revealed that Umifenovir, when compared to certain other antiviral treatments, led to a significantly shorter duration of hospitalization and demonstrated marked clinical and laboratory improvements. Patients receiving Umifenovir showed enhanced peripheral oxygen saturation and favorable changes in white blood cell counts and erythrocyte sedimentation rates. Importantly, the incidence of adverse events, such as nausea and vomiting, was reported to be lower in the Umifenovir group, indicating a more favorable safety profile. These findings underscore its potential to contribute to better patient outcomes, including a reduced need for intensive care unit admissions and improved resolution of chest CT involvements.

For pharmaceutical manufacturers and suppliers seeking a reliable source of high-quality Arbidol HCl (Umifenovir) with CAS 131707-23-8, NINGBO INNO PHARMCHEM CO.,LTD. offers a product that meets stringent quality standards such as ISO 9001, USP, and BP. We ensure consistent purity, critical for downstream pharmaceutical applications. Our dedication to quality and supply chain integrity makes us an ideal partner for purchasing bulk quantities of this essential antiviral intermediate. For detailed price information and to discuss your specific requirements, please reach out to our sales team.